v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Collaboration and license $ 0 $ 400
Grant 78 700
Total revenues 78 1,100
Operating expenses:    
Research and development 19,463 14,674
General and administrative 7,114 8,315
Total operating expenses 26,577 22,989
Operating loss (26,499) (21,889)
Other (expense) income:    
Interest income 1,026 2,015
Gain on change in fair value of warrant liabilities 94 1,818
(Loss) gain on change in fair value of contingent value right liability (13,800) 346
Other expense, net (3) 0
Total other (expense) income, net (12,683) 4,179
Net loss (39,182) (17,710)
Other comprehensive (loss) income:    
Foreign currency translation adjustment (7) 32
Total comprehensive loss $ (39,189) $ (17,678)
Net loss per share allocable to common stockholders:    
Basic (in dollars per share) $ (1.46) $ (0.68)
Diluted (in dollars per share) $ (1.46) $ (0.68)
Weighted-average common shares outstanding:    
Basic (in shares) 26,855,158 25,902,650
Diluted (in shares) 26,855,158 25,902,650